Carl Zeiss Meditec AG is set to expand its ophthalmic presence by acquiring 100% of the shares in the Dutch Ophthalmic Research Center (International) B.V. (D.O.R.C.) from the investment firm Eurazeo SE, Paris, France.
The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma, and refractive errors.
D.O.R.C.’s devices, disposables and liquids for ophthalmic surgeries, which are used to treat a wide range of vision-threatening conditions, are a strong complement to the ZEISS Medical Technology portfolio.
The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions
The portfolio also includes the EVA NEXUS platform, comprising of a dual-capable system and a full range of accessories, instruments and liquids, offering a best-in-class solution across vitreoretinal, cataract, and combined procedures.
“With the acquisition of Dutch Ophthalmic Research Center, we’ll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreoretinal surgery segment and extend our leadership in the ophthalmic medical devices market,” said Dr Markus Weber, President and CEO of Carl Zeiss Meditec AG.
Professor Euan S. Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology said the acquisition will “greatly enhance our ZEISS Retina Workflow and overall portfolios for both posterior and anterior surgery segments, helping to firmly establish our position as a leading solutions provider in the global retinal surgery market.”
The acquisition is valued at approximately EUR 985 million and is expected to close in the first half of this calendar year. The transaction remains subject to applicable regulatory and antitrust approvals.
